Le Lézard
Classified in: Health
Subject: SVY

European Panic Disorder Market Outlook to 2026: Analysis on Epidemiology, Patient Flow, Prevalence and Diagnosed & Treated Patients


DUBLIN, July 13, 2018 /PRNewswire/ --

The "Europe Panic Disorder Epidemiology and Patient Flow Analysis - 2018" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The research provides insights into Panic Disorder epidemiology, Panic Disorder diagnosed patients, and Panic Disorder treatment rate for EU5 countries. The research measures key indicators including prevalence of Panic Disorder derived from epidemiological analysis, patients diagnosed with Panic Disorder, and patients treated with a drug therapy.

The research study helps executives estimate Panic Disorder market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The research provides estimates and forecasts of Panic Disorder prevalence, Panic Disorder diagnosis rate, and Panic Disorder treatment rate for the period 2017-2026. The information is presented by EU5 countries including Germany, France, Spain, Italy, and UK.


Key Topics Covered




1. Panic Disorder: Disease Definition



2. Panic Disorder Patient Flow in Europe


2A. Panic Disorder Prevalence in Europe


2B. Panic Disorder Diagnosed Patients in Europe


2C. Panic Disorder Treated Patients in Europe



3. Panic Disorder Patient Flow in Germany


3A. Panic Disorder Prevalence in Germany


3B. Panic Disorder Diagnosed Patients in Germany


3C. Panic Disorder Treated Patients in Germany



4. Panic Disorder Patient Flow in France


4A. Panic Disorder Prevalence in France


4B. Panic Disorder Diagnosed Patients in France


4C. Panic Disorder Treated Patients in France



5. Panic Disorder Patient Flow in Spain


5A. Panic Disorder Prevalence in Spain


5B. Panic Disorder Diagnosed Patients in Spain


5C. Panic Disorder Treated Patients in Spain



6. Panic Disorder Patient Flow in Italy


6A. Panic Disorder Prevalence in Italy


6B. Panic Disorder Diagnosed Patients in Italy


6C. Panic Disorder Treated Patients in Italy



7. Panic Disorder Patient Flow in UK


7A. Panic Disorder Prevalence in UK


7B. Panic Disorder Diagnosed Patients in UK


7C. Panic Disorder Treated Patients in UK



8. Research Methodology



For more information about this report visit

https://www.researchandmarkets.com/research/3vdn2x/european_panic?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:


Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 



SOURCE Research and Markets


These press releases may also interest you

at 21:27
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...

at 19:30
Astellas Pharma Inc....

at 19:15
Denver nonprofit Justice Necessary unveils data from its latest study on teen period poverty in Colorado, shedding light on a deeply concerning issue. The findings of this study underscore the urgent need for action to address the need for teens to...

at 19:05
Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies. A joint incubation by ARCH Venture Partners and Foresite Labs, Xaira launched...

at 18:00
Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM. MamaLift Plus is the first prescription digital therapeutic for the treatment of postpartum depression (PPD), a...

at 17:45
BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada between April 30th ? May 2nd at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of BioSyent,...



News published on and distributed by: